MindMed to Host Conference Call and Webcast to Discuss Third Quarter 2023 Financial Results and Provide Business UpdateBusiness Wire • 10/26/23
MindMed Completes Enrollment of Phase 2a Trial of MM-120 in Adults with Attention-Deficit/Hyperactivity Disorder (ADHD)Business Wire • 10/24/23
MindMed to Present Data on the Preclinical Activity of MM-402 at the 36th Annual European College of Neuropsychopharmacology (ECNP) CongressBusiness Wire • 10/03/23
MindMed to Participate in the TD Cowen 3rd Annual Novel Mechanisms in Neuropsychiatry SummitBusiness Wire • 09/14/23
MindMed Completes Enrollment of Phase 2b Trial of MM-120 in Generalized Anxiety Disorder (GAD)Business Wire • 09/12/23
MindMed Reports Second Quarter 2023 Financial Results and Business HighlightsBusiness Wire • 08/03/23
MindMed Announces Exclusive License Agreement With Catalent for Its Patented Zydis® Fast-Dissolve Technology for Use with MM-120Business Wire • 08/03/23
MindMed to Host Conference Call and Webcast to Discuss Second Quarter 2023 Financial Results and Provide Business UpdateBusiness Wire • 07/31/23
Psychedelic clinical trials: A glimpse at hotly-anticipated upcoming resultsProactive Investors • 06/27/23
MindMed to Participate in the H.C. Wainwright 4th Annual Neuropsychiatry Virtual ConferenceBusiness Wire • 06/22/23
TOMS Shoes founder is pledging $100 million for psychedelic research – Here's why he's doing it.Market Watch • 06/21/23
MindMed Provides Overview of Clinical Progress and Corporate Updates at Investor DayBusiness Wire • 06/20/23
MindMed Urges Shareholders to Vote TODAY for Company Nominees Ahead of June 13th DeadlineBusiness Wire • 06/09/23
Leading Proxy Advisory Firm Glass Lewis Recommends MindMed Shareholders Vote FOR All Six Company NomineesBusiness Wire • 06/08/23
Leading Proxy Advisory Firm ISS Recommends MindMed Shareholders Vote FOR All Six Company NomineesBusiness Wire • 06/05/23